Document:

Form of Change of Control Agreement for Officers

 Exhibit 10.7 
 ACCLARENT, INC. 
 CHANGE OF CONTROL SEVERANCE AGREEMENT 
 This Change of Control Severance Agreement (the “Agreement”) is made and entered into by and between
                     (“Employee”) and Acclarent, Inc. (the “Company”), effective as of
                    , 2008 (the “Effective Date”). 
 RECITALS 
 1. It is expected that the Company from time to time will consider the possibility
of an acquisition by another company or other Change of Control. The Board of Directors of the Company (the “Board”) recognizes that such consideration can be a distraction to Employee and can cause Employee to consider alternative
employment opportunities. The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Employee, notwithstanding the possibility,
threat or occurrence of a Change of Control (as defined herein) of the Company. 
 2. The Board believes that it is in the best interests of
the Company and its stockholders to provide Employee with an incentive to continue his or her employment and to motivate Employee to maximize the value of the Company upon a Change of Control for the benefit of its stockholders. 
 3. The Board believes that it is imperative to provide Employee with certain benefits upon a Change of Control and with certain severance benefits upon
Employee’s termination of employment following a Change of Control. These benefits will provide Employee with enhanced financial security and incentive and encouragement to remain with the Company notwithstanding the possibility of a Change of
Control. 
 4. Certain capitalized terms used in the Agreement are defined in Section 5 below. 
 AGREEMENT 
 NOW, THEREFORE, in
consideration of the mutual covenants contained herein, the parties hereto agree as follows: 
 1. Term of Agreement. This Agreement
will terminate upon the date that all of the obligations of the parties hereto with respect to this Agreement have been satisfied. 
 2.
At-Will Employment. The Company and Employee acknowledge that Employee’s employment is and will continue to be at-will, as defined under applicable law. If Employee’s employment terminates for any reason, including (without
limitation) any termination prior to a Change of Control, Employee will not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement or under the terms of any written formal employment agreement
or fully executed offer letter between the Company and Employee (an “Employment Agreement”). 

 3. Severance Benefits. 
 (a) Involuntary Termination Within Twelve Months Following a Change of Control. If within twelve (12) months following a Change of Control,
(i) the Company (or any parent or subsidiary of the Company) terminates Employee’s employment without Cause or (ii) Employee terminates Employee’s employment with the Company (or any parent or subsidiary of the Company) for Good
Reason, then, subject to Subsections 3(c) and 3(d) below, Employee will receive the following: 
 (i) Continuing payments of severance pay
at a rate equal to Employee’s base salary rate (less applicable withholding taxes), (as in effect immediately prior to (A) the Change of Control, or (B) Employee’s termination, whichever is greater), for [ENTER six (6) OR
twelve (12)] months from the date of such termination of employment, to be paid periodically in accordance with the Company’s normal payroll policies; and 
 (ii) If Employee elects to continue his or her medical coverage under Title X of the Consolidated Budget Reconciliation Act of 1985 (“COBRA”), the Company will reimburse the cost of COBRA coverage for
Employee and Employee’s eligible dependents for [ENTER six (6) OR twelve (12)] months following the date of Employee’s termination of employment with the Company (or if earlier, until Employee ceases to be eligible for COBRA).

 (b) Termination without Cause Prior to a Change of Control or After Twelve Months Following a Change of Control. If prior to a
Change of Control or after twelve (12) months following a Change of Control, (i) the Company (or any parent or subsidiary of the Company) terminates Employee’s employment without Cause or (ii) Employee terminates employment with
the Company (or any parent or subsidiary of the Company) for Good Reason, then Employee will not be entitled to receive severance or other benefits except for those (if any) as may then be established under other written agreements with the Company,
including, without limitation, any Employment Agreement. 
 (c) Release of Claims Agreement. The receipt of any severance pay or other
benefits pursuant to Subsection 3(a) above will be subject to Employee signing and not revoking a release of claims agreement with the Company in a form acceptable to the Company and such release becoming effective no later than March 15 of the
calendar year following the calendar year in which such termination occurs. No such severance pay or other benefits will be paid or provided until the release of claims agreement becomes effective, and any severance amounts or benefits otherwise
payable between the date of Employee’s termination and the date of such release becomes effective shall be paid on the effective date of such release. 
 (d) Non-solicitation and Non-competition. Employee agrees, to the extent permitted by applicable law, that in the event Employee receives severance pay or other benefits pursuant to Subsection 3(a) above, for
the [ENTER six (6) OR twelve (12)] consecutive month period immediately following the date of Employee’s termination, Employee, as a condition to receipt of severance pay and benefits under Subsection 3(a), will not (i) either
directly or indirectly, solicit, induce, recruit, or encourage any employee of the Company to leave his employment either for Employee or for any other entity or person, or (ii) without the express written consent of the 

  

 -2- 

 
Company, directly or indirectly engage in, enter the employ, have any ownership interest in, or participate in any entity that as of the date of involuntary
termination, engages in the design, development, manufacture, production, marketing, sale or servicing of any product or the provision of any service that competes with any service offered by the Company or any product sold by the Company or under
development by the Company; provided, however, that ownership of less than one percent (1%) of the outstanding stock of any publicly traded corporation will not be deemed to be violative of the restrictive covenant set forth in this paragraph.

 The covenants contained in this Subsection 3(d) hereof shall be construed as a series of separate covenants, one for each country,
province, state, city or other political subdivision in which the Company currently engages in its business or, during the term of this Agreement, becomes engaged in its business. Except for geographic coverage, each such separate covenant shall be
deemed identical in terms to the covenant contained in this Subsection 3(d). If, in any judicial proceeding, a court refuses to enforce any of such separate covenants (or any part thereof), then such unenforceable covenant (or such part) shall be
eliminated from this Agreement to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. In the event that the provisions of this Subsection 3(d) are deemed to exceed the time, geographic or scope
limitations permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case may be, permitted by applicable law. 
 (e) Timing of Severance Payments. The Company will pay the severance payments to which Employee is entitled as salary continuation on the same
basis and timing as in effect immediately prior to the Change of Control. If Employee should die before all amounts have been paid, such unpaid amounts will be paid in a lump-sum payment (less any withholding taxes) to Employee’s designated
beneficiary, if living, or otherwise to the personal representative of Employee’s estate. 
 (f) Voluntary Resignation; Termination
For Cause. If Employee’s employment with the Company terminates (i) voluntarily by Employee (except upon a termination for Good Reason within twelve (12) months following a Change of Control) or (ii) for Cause by the Company
(or any parent or subsidiary of the Company), then Employee will not be entitled to receive severance or other benefits except for those (if any) as may then be established under other written agreements with the Company, including, without
limitation, any Employment Agreement. 
 (g) Disability; Death. If the Company terminates Employee’s employment as a result of
Employee’s Disability, or Employee’s employment terminates due to his or her death, then Employee will not be entitled to receive severance or other benefits except for those (if any) as may then be established under the Company’s
then existing written severance and benefits plans and practices or pursuant to other written agreements with the Company, including, without limitation, any Employment Agreement. 
 (h) Exclusive Remedy. In the event of a termination of Employee’s employment with the Company (or any parent or subsidiary of the Company),
the provisions of this Section 3 are intended to be and are exclusive and in lieu of any other rights or remedies to which Employee or the Company may otherwise be entitled, whether at law, tort or contract, in equity, or under this Agreement.
Employee will be entitled to no benefits, compensation or other payments or rights upon termination of employment other than those benefits expressly set forth in this Section 3. 
  

 -3- 

 (i) Section 409A. 
 (i) Notwithstanding anything to the contrary in this Agreement, if Employee is a “specified employee” within the meaning of Section 409A
of the Internal Revenue Code of 1986, as amended and any final regulations and guidance promulgated thereunder (“Section 409A”) at the time of Employee’s termination (other than due to death), then the severance payable to
Employee, if any, pursuant to this Agreement, when considered together with any other severance payments or separation benefits that are considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation
Benefits”), that are payable within the first six (6) months following Employee’s termination of employment will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day
following the date of Employee’s termination of employment. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding
anything herein to the contrary, if Employee dies following his or her termination but prior to the six (6) month anniversary of his or her termination, then any payments delayed in accordance with this paragraph will be payable in a lump sum
as soon as administratively practicable after the date of Employee’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment
payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (ii) Any amount paid under the Agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation
Benefits for purposes of Subsection 3(i)(i) above. 
 (iii) Any amount paid under the Agreement that qualifies as a payment made as a result
of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that do not exceed the Section 409A Limit will not constitute Deferred Compensation Separation Benefits for purposes of
Subsection 3(i)(i) above. 
 It is the intent of this Agreement to comply with the requirements of Section 409A so that none of the
severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. Employee and the Company agree to work together in good
faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Employee under
Section 409A. 
 4. Limitation on Payments. In the event that the severance and other benefits provided for in this Agreement or
otherwise payable to Employee (i) constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and (ii) but for this Section 4, would be subject
to the excise tax imposed by Section 4999 of the Code, then Employee’s severance benefits under Subsection 3(a) will be payable either: 
  

 -4- 

	 	(a)	in full, or 

  

	 	(b)	as to such lesser extent which would result in no portion of such severance benefits being subject to excise tax under Section 4999 of the Code, 

 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999, results in
the receipt by Employee on an after-tax basis, of the greatest amount of severance benefits, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. Unless the Company and Employee
otherwise agree in writing, any determination required under this Section 4 will be made in writing by the Company’s independent public accountants immediately prior to Change of Control (the “Accountants”), whose determination will
be conclusive and binding upon Employee and the Company for all purposes. For purposes of making the calculations required by this Section 4, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may
rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Employee will furnish to the Accountants such information and documents as the Accountants may reasonably request in
order to make a determination under this Section. The Company will bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 4. If a reduction in payments or benefits constituting
“parachute payments” is necessary so that they do not constitute “parachute payments,” reduction will occur in the following order: reduction of cash payments; reduction of employee benefits; cancellation of accelerated vesting
of equity awards; cancellation of equity awards that are considered to be “contingent” upon the Change of Control transaction. 
 5. Definitions. The following terms referred to in this Agreement will have the following meanings: 
 (a) Cause.
“Cause” means (i) Employee’s repeated failure, in the reasonable judgment of the Board of Directors, to substantially perform his or her assigned duties or responsibilities as a service provider as directed or assigned by the
Company’s Board of Directors [or such Employee’s immediate supervisor] (other than a failure resulting from the Employee’s Disability) after written notice thereof from the Company’s Board of Directors [or such Employee’s
immediate supervisor] to Employee describing in reasonable detail Employee’s failure to perform such duties or responsibilities and Employee having had the opportunity to address the Board, with counsel, regarding such alleged failures and his
or her failure to remedy same within 30 days of receiving written notice; (ii) Employee engaging in knowing and intentional illegal conduct that was or is materially injurious to the Company or its affiliates; (iii) Employee’s
violation of a federal or state law or regulation applicable to the Company’s business which violation was or is reasonably likely to be injurious to the Company; (iv) Employee’s gross negligence or willful misconduct;
(v) Employee’s material breach of this Agreement or the terms of any confidentiality agreement or invention assignment agreement between Employee and the Company; or (vi) Employee being convicted of, or entering a plea of nolo
contendere to, a felony or committing any act of moral turpitude, dishonesty or fraud against, or the misappropriation of material property belonging to, the Company or its affiliates. 
 (b) Change of Control. “Change of Control” of the Company means: 
 (i) A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group
(“Person”), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company; provided, however, that for purposes of this
subsection (i), the acquisition of additional stock by any one Person, who is considered to own more than 50% of the total voting power of the stock of the Company will not be considered a Change of Control; or 
  

 -5- 

 (ii) A change in the effective control of the Company which occurs on the date that a majority of
members of the Board (each, a “Director”) is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or
election. For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change of Control; or 

(iii) A change in the ownership of a substantial portion of the Company’s assets which occurs on the date that any Person acquires (or has
acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market
value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of
the Company’s assets: (A) a transfer to an entity that is controlled by the Company’s stockholders immediately after the transfer, or (B) a transfer of assets by the Company to: (1) a stockholder of the Company (immediately
before the asset transfer) in exchange for or with respect to the Company’s stock, (2) an entity, 50% or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3) a Person, that owns,
directly or indirectly, 50% or more of the total value or voting power of all the outstanding stock of the Company, or (4) an entity, at least 50% of the total value or voting power of which is owned, directly or indirectly, by a Person
described in this subsection (iii)(B)(3). For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities
associated with such assets. 
 For purposes of this definition of Change of Control, persons will be considered to be acting as a group if
they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. 
 (c) Disability. “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code. 
 (d) Good Reason. “Good Reason” means Employee’s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or
more of the following, without Employee’s consent: (i) without Employee’s express written consent, the assignment to Employee of any duties or the reduction of Employee’s duties, either of which results in a significant
diminution in Employee’s position or responsibilities 

  

 -6- 

 
with the Company in effect immediately prior to such assignment, or removal of Employee from such position and responsibilities; (ii) a material
reduction by the Company in Employee’s annualized base pay as in effect immediately prior to such reduction; or (iii) the relocation of Employee’s principal place of performing his or her duties as an employee of the Company by more
than fifty (50) miles. In order for an event to qualify as Good Reason, Employee must not terminate employment with the Company without first providing the Company with written notice of the acts or omissions constituting the grounds for
“Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of not less than thirty (30) days following the date of such notice. 
 (e) Section 409A Limit. “Section 409A Limit” means the lesser of two (2) times: (i) Employee’s annualized
compensation based upon the annual rate of pay paid to Employee during the Company’s taxable year preceding the Company’s taxable year of Employee’s termination of employment as determined under Treasury Regulation
1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in
which Employee’s employment is terminated. 
 6. Successors. 
 (a) The Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation,
liquidation or otherwise) to all or substantially all of the Company’s business and/or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the
same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” will include any successor to the Company’s business and/or assets
which executes and delivers the assumption agreement described in this Section 6(a) or which becomes bound by the terms of this Agreement by operation of law. 
 (b) Employee’s Successors. The terms of this Agreement and all rights of Employee hereunder will inure to the benefit of, and be enforceable by, Employee’s personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees and legatees. 
 7. Notice. 
 (a) General. Notices and all other communications contemplated by this Agreement will be in writing and will be deemed to have been duly given when
personally delivered or when mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of Employee, mailed notices will be addressed to him or her at the home address which he or she most recently
communicated to the Company in writing. In the case of the Company, mailed notices will be addressed to its corporate headquarters, and all notices will be directed to the attention of its General Counsel. 
 (b) Notice of Termination. Any termination by the Company for Cause or by Employee for Good Reason or as a result of a voluntary resignation will
be communicated by a 

  

 -7- 

 
notice of termination to the other party hereto given in accordance with Subsection 7(a) of this Agreement. Such notice will indicate the specific
termination provision in this Agreement relied upon, will set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination under the provision so indicated, and will specify the termination date (which will be
not more than thirty (30) days after the giving of such notice). The failure by Employee to include in the notice any fact or circumstance which contributes to a showing of Good Reason will not waive any right of Employee hereunder or preclude
Employee from asserting such fact or circumstance in enforcing his or her rights hereunder. 
 8. Term of Agreement. This Agreement
will have a term of ten (10) years commencing on the Effective Date, which shall not be subject to renewal, unless a Change of Control occurs during such ten-year period, in which case this Agreement will continue until all payments and
benefits to which Employee otherwise may become entitled, if any, have been made to Employee.  
 9. Arbitration. Employee and
the Company agree that any and all disputes arising out of, or relating to, the terms of this Agreement, their interpretation, and any of the matters herein, will be subject to binding arbitration in San Mateo County, California before the Judicial
Arbitration & Mediation Services (“JAMS”) pursuant to its employment arbitration rules & procedures (“JAMS Rules”). The arbitrator shall administer and conduct any arbitration in accordance with California law,
including the California Code of Civil Procedure, and the arbitrator shall apply substantive and procedural California law to any dispute or claim, without reference to any conflict-of-law provisions of any jurisdiction. To the extent that the JAMS
Rules conflict with California law, California law will take precedence. The Company and Employee agree that the prevailing party in any arbitration will be entitled to injunctive relief in any court of competent jurisdiction to enforce the
arbitration award. The Company and Employee agree that the prevailing party in any arbitration will be awarded its reasonable attorneys’ fees and costs. The Company and Employee hereby agree to waive their right to have any dispute with the
other party resolved in a court of law by a judge or jury. This Section 9 will not prevent either party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the parties and the subject matter
of their dispute relating to Employee’s obligations under this Agreement and the agreements incorporated herein by reference. 
 10.
Miscellaneous Provisions. 
 (a) No Duty to Mitigate. Employee will not be required to mitigate the amount of any payment
contemplated by this Agreement, nor will any such payment be reduced by any earnings that Employee may receive from any other source. 
 (b)
Waiver. No provision of this Agreement will be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Employee and by an authorized officer of the Company (other than Employee). No
waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party will be considered a waiver of any other condition or provision or of the same condition or provision at another time.

  

 -8- 

 (c) Headings. All captions and section headings used in this Agreement are for convenient
reference only and do not form a part of this Agreement. 
 (d) Entire Agreement. This Agreement, together with any Employment
Agreement, constitutes the entire agreement of the parties hereto. 
 (e) Choice of Law. The validity, interpretation, construction
and performance of this Agreement will be governed by the laws of the State of California (with the exception of its conflict of laws provisions). 
 (f) Severability. The invalidity or unenforceability of any provision or provisions of this Agreement will not affect the validity or enforceability of any other provision hereof, which will remain in full force and effect.

 (g) Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable income and employment
taxes. 
 (h) Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument. 
 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of
the Company by its duly authorized officer, as of the day and year set forth below. 
  

					
	COMPANY	 	ACCLARENT, INC.
			
		 	By:	 	  

		 	Title:	 	  

			
	EMPLOYEE	 		 	
		 	By:	 	  

		 	Title:	 	  

  

 -9-Manufacture and Supply Agreement - Advanced Polymers, Inc and amendments thereto

 Exhibit 10.9 
 MANUFACTURE 
 AND SUPPLY AGREEMENT 
 THIS MANUFACTURE AND SUPPLY AGREEMENT is made as of September 8, 2005 (the “Effective Date”), by and between ACCLARENT, INC., a Delaware
Corporation with a principal place of business in Menlo Park, California, and with a mailing address of 1525-B O’Brien Drive, Menlo Park, California, 94025 (hereinafter referred to as Acclarent), and ADVANCED POLYMERS, INC., a New
Hampshire corporation duly organized and existing under the laws of the State of New Hampshire, having its principal place of business in Salem, New Hampshire, and with a mailing address of 29 Northwestern Drive, Salem, New Hampshire, 03079,
(hereinafter referred to as Advanced). 
 RECITALS 
 A. Advanced has developed and designed, and currently manufactures to specifications provided by Acclarent, certain balloons and balloon catheters to be used in the treatment of disorders of the Ears, Nose and Throat
(hereinafter ENT) and agrees to supply these balloons and balloon catheters to Acclarent pursuant to the terms of this Agreement. 
 B.
Acclarent is in the business of designing, developing and selling devices and methods for use in the ENT field. 
 C. Acclarent desires to
buy from Advanced, and Advanced desires to sell to Acclarent the Product, as defined below, pursuant to the terms and conditions as outlined in this Agreement. 
 NOW THEREFORE, in consideration of the promises and the mutual covenants hereinafter set forth, the parties hereto have agreed as follows: 
 ARTICLE 1 - DEFINITIONS 
 As used herein, the following terms shall have the meanings set forth
below: 
 1.1 “Affiliate” shall mean any entity controlling, controlled by or under common control with a party hereto. For purposes
hereto “control” shall mean ownership, directly or indirectly, of at least 50% of the securities having the right to vote for election of directors, in the case of a corporation, and at least 50% of the beneficial interest in the capital,
in the case of a business entity other than a corporation. 
 1.2 “[****] Technology” shall mean the materials and methods used by
Advanced for [****] of any [****] included in the Product. 
 1.3 “Confidential Information” shall mean the terms of this
agreement, and all proprietary information of a party, including, without limitation, any know-how, specifications, diagrams, information, data, materials, prototypes or models relating to the Product, markets, customers, 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
suppliers, inventions, Product, procedures, designs, research and development, business plans, financial projections, organizations, employees or consultants
or any other similar aspects of the present or future business of such party, the secrecy of which has value to and/or confers a competitive advantage upon that party. 
 1.4 “Excluded Technology” shall mean the following patents owned by Advanced, which shall be specifically excluded from this Agreement, regardless of whether the same fall in the Field of Use or not, namely,
Patent Numbers [****]. This Agreement shall also exclude certain patents related to heating and cooling fluids within a blood vessel and heating and cooling cerebral spinal fluid. 
 1.5 “Field of Use” shall be defined as the [****]. 
 1.6 “Intellectual Property Rights” shall mean patent rights, copyrights, trade secret rights or any other intellectual property rights. 
 1.7 “Product” shall mean Balloons and Balloon Catheters for use [****] including the present design as described in the Recitals as
manufactured in accordance with the Specifications (as defined below), and any improvements or modifications thereto developed or otherwise controlled by Advanced that Acclarent elects to incorporate into the Product and include as part of the
Specifications. As used in this Agreement, “Balloons” shall be defined as all non-compliant and semi-compliant balloons, [****], having a useable [****] (compliance) of [****]. For purposes of this Agreement, balloons made of materials
such as silicone or latex and having useable [****] (compliance) [****] shall be deemed to be compliant and shall thus be excluded from this Agreement. 
 1.8 “Specifications” shall mean those specifications for the initial Product attached hereto as Exhibit A. 
 1.9 “Resulting Intellectual Property” shall mean any Intellectual Property Rights that have resulted from, or subsequently result from, work performed a) jointly by Acclarent and Advanced and/or
b) by one party at the request of the other party. 
 ARTICLE 2 - MANUFACTURE AND SUPPLY OF PRODUCT 
 2.1 Manufacture and Supply of Product. Subject to the terms and conditions set forth in this Agreement, Advanced shall manufacture the Product for
sale to Acclarent in the Field of Use and shall supply Acclarent’s requirements for such Product in the Field Of Use as set forth below. All Product manufactured hereunder shall meet the Specifications as set forth in Exhibit A and as may
be revised from time to time upon written agreement of the parties and shall be subject to the terms of Section 16.10 below. All Product shall be labeled and packaged in accordance with Acclarent’s written instructions therefore as
reasonably provided by Acclarent to Advanced. Advanced agrees to comply with all applicable laws and regulations and to maintain ongoing quality assurance and testing procedures to satisfy and ensure compliance with the QA Standards (as defined in
Section 7.1 below). Advanced will maintain, and will allow Acclarent, any designee of Acclarent 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
or any governmental agency having appropriate authority, to examine its manufacturing facility and its manufacturing and quality assurance records, such
records being limited to those records required by law or regulation as well as lot numbers and other manufacturing documentation reasonably required to ensure traceability of the Product, PROVIDED, HOWEVER, Advanced shall have the right to restrict
access or redact portions of documents as required to protect its confidential, proprietary or trade secret information. 
 2.2 Materials,
Specification, and Process Changes. Any changes requested by either party relating to materials, specifications, or manufacturing processes for the Product, and any engineering charges or other charges or price increases related to changes in
materials, specifications and/or changes in processes shall be subject to prior written approval of the other party. 
 2.3 Purchase of
Product. Subject to the terms and conditions set forth in this Agreement, Acclarent shall purchase from Advanced [****] Product to be sold by Acclarent in the United States or countries other than the United States. Provided, however, that
a) subject to the confidentiality provisions of Article 13 below, nothing in this agreement shall prevent Acclarent from purchasing Product from any third party vendor [****] and/or b) purchasing Product for resale from a third party
vendor [****]. It is expressly understood by the parties that this paragraph does not allow Acclarent to [****]. 
 2.4 Forecasts. On
or before [****], Acclarent shall provide to Advanced an initial [****] forecast for Acclarent’s purchase of Product to commence effective [****]. 
 As set forth in Section 2.5 below, Acclarent will then provide purchase orders for actual purchases of Product. All forecasts shall be [****] and pricing for Product (as outlined on Exhibit A) shall be based
on actual Product purchased. In the event that Product purchased by Acclarent is between price breaks as outlined on Exhibit A, Advanced shall provide a prorated price. 
 Said forecast shall be updated on at least a [****] basis, commencing with the fourth month for which the forecast is provided. Said update will be
provided by Acclarent no later than the [****] of the start of each [****], and shall comply with the preceding paragraph. In the event that Acclarent fails to provide an updated written forecast on or before the [****] of the start of any given
[****], the forecast provided to Advanced for the next [****] on the previously provided forecast shall constitute [****] forecast for such quarter, irrespective of any purchase orders or actual purchases. 
 2.5 Purchase Orders. Acclarent shall submit written purchase orders for the purchase of its requirements for the Product, which shall set forth
the quantities ordered, the requested delivery dates, shipping instructions and shipping addresses. Purchase Orders shall be [****] for the entire amount ordered. Acclarent shall be entitled to use its standard form of purchase order; provided,
however that such purchase orders shall not alter any of the terms contained in this Agreement. In the event of any conflict between the terms of any purchase order delivered by Acclarent hereunder and the terms of this Agreement, the terms of this
Agreement shall control. The purchase order(s) can be amended to comply with any changes in the forecast. Any amendment to a purchase order shall reflect the original purchase order number submitted by Acclarent to Advanced with the initial
forecast. This Paragraph shall also be subject to the terms of Article 3 below relating to exclusivity. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 2.6 Acceptance or Rejection of Purchase Orders. Advanced shall acknowledge Acclarent’s
purchase orders in writing and shall be entitled to reject that portion of any purchase order for Balloons in quantities greater than [****] of forecast or in the case of assembled Balloon Catheters, Advanced shall be entitled to reject that portion
of any purchase order requiring delivery of more than [****] assembled Balloon Catheters within any calendar month; provided, however, that Advanced shall use commercially reasonable efforts to supply ordered quantities in excess of the above-stated
[****] of the forecast for Balloons or [****] assembled Balloon Catheters per month. In the event that Advanced rejects a portion(s) of any purchase order(s) pursuant to this paragraphs 2.6, Acclarent shall [****] purchase balloons or assembled
catheters from a third party to fill the rejected portion(s) of such purchase order(s). Advanced shall not be considered in breach of this Agreement in the event that it cannot provide assembled Balloon Catheters in excess of [****] per month. Any
full or partial rejection of Acclarent’s purchase order must be communicated in writing to Acclarent within ten (10) business days of receipt of the purchase order by Advanced. Any purchase order for Balloons in quantities equal to or less
than [****] of the forecast or any purchase order requiring delivery of fewer than [****] assembled Balloon Catheters per month shall be accepted by Advanced, provided compliance with Paragraph 2.7 below. Acceptance by Advanced of a purchase
order or cumulative orders for an amount(s) less than the forecasted amount(s) shall not constitute a modification of the forecast and Acclarent shall [****] forecast as set forth above. No course of dealing between the parties shall alter
Acclarent’s obligations pursuant to the forecast. 
 2.7 Purchase Order Lead Times. Acclarent will provide purchase orders to
Advanced at least [****] in advance of the first delivery date for assembled Balloon Catheters and at least [****] in advance of the delivery date for Balloons that are less than or equal to [*****] of the forecast, and [****] in advance of the
delivery date for Balloons that are between [****] and [****] of the forecast. 
 ARTICLE 3 - MUTUAL EXCLUSIVITY AND TECHNOLOGY
TRANSFER 
 3.1 Exclusivity by Advanced. Advanced agrees not to knowingly supply any person or entity other than Acclarent with
Product or other balloons for sale or use in the Field of Use or to train or assist others in the manufacture of any balloon or balloon catheter for use in the Field of Use, so long as this Agreement remains in force and the exclusivity payments
have been made. For sales to third parties of Product or any balloons that are [****] or have [****], Advanced will use reasonable efforts to ensure that the third party making such purchase does not intend to sell or use the Product or balloons in
the Field of Use. If Acclarent identifies any third party who is selling or using any Product or any balloons within the Field of Use, Acclarent will promptly notify Advanced in writing and if that third party is acquiring the Product or balloons
from Advanced, Advanced will immediately cease all supply of such Product or balloons to that third party. 
 3.2 Technology Transfer.
Advanced agrees to transfer to Acclarent information relating to [****] as defined in the [****] for use in the Field of Use as defined in this Agreement. Specifically excluded from this Technology Transfer shall be the [****] as defined herein as
well as Advanced’s [****]. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 The Technology Transfer shall commence during the fourth quarter of 2005, and it is anticipated that it
shall conclude by the end of 2005. 
 Acclarent shall send no more than six (6) engineers, quality engineers, operators or assemblers to
Advanced for the Technology Transfer. It is anticipated that the Technology Transfer should be complete in two (2) to four (4) weeks’ time. It is further agreed and understood that there shall be no more than three (3) Acclarent
employees at Advanced at any one time unless agreed to by Advanced in advance. 
 Employees of Advanced shall be compensated at the following
rates for the training conducted by employees for the benefit of Acclarent: 
  

	 	a.	[****]: [****] per hour; 

  

	 	b.	Engineers and Managers: [****] per hour; 

  

	 	c.	Supervisors and Trainers: [****] per hour; 

  

	 	d.	Assemblers: [****] per hour. 

 All time spent by Advanced
in regard to the Technology Transfer shall commence accruing as of the date of execution of this Agreement. Advanced does hereby further agree that it shall provide eight (8) hours of training, per Advanced employee assisting with the training,
at no cost to Acclarent. After said eight (8) hours per Advanced employee assisting with the training, time shall be billed to Acclarent on a monthly basis, and payment for the same shall be due and payable upon receipt, and no later than
thirty (30) days from the date of the invoice. 
 It is expressly agreed and understood that Advanced has no obligation to assist with
the Technology Transfer outside of Advanced’s premises, i.e., no obligation to provide assistance in house at Acclarent. Advanced will, however, provide telephone assistance and support when requested by Acclarent at the prices specified above.

 Additionally, Advanced shall have no obligation to provide any additional documentation, testing, validations, etc., relative to the
Technology Transfer. If Acclarent requires any further documentation, testing, validations, etc., and provided that Advanced agrees to the same, Acclarent shall compensate Advanced at the rates indicated above. 
 In consideration of Advanced’s transfer of technology as defined above, Acclarent shall pay to Advanced the sum of [****] shall be paid to Advanced
upon the execution of this Agreement. The balance of said sum, namely [****] shall be paid to Advanced upon the completion of the Technology Transfer. The Technology Transfer shall be deemed complete upon transfer to Acclarent of all know-how and
confidential information reasonably necessary to enable Acclarent to 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
commercially manufacture saleable Balloon Catheters in Acclarent’s facility by the same manufacturing processes, materials and techniques that have been
used by Advanced to manufacture those Balloon Catheters in its own facility. 
 3.3 Prepayments in Consideration of Exclusivity. In
consideration of Advanced’s covenant of exclusive supply pursuant to Section 3.1., above, Acclarent shall, upon execution of this Agreement, pay to Advanced the sum of [****]. On the [****] of this Agreement, Acclarent shall pay to
Advanced the sum of [****]. On the [****] of this Agreement, Acclarent shall pay to Advanced the sum of [****]. The [****] payments regarding exclusivity (i.e., payments totaling [****]) are not optional payments and failure of Acclarent to pay the
same shall be considered a breach of this Agreement subject to the terms of Article 16.10 below. On the [****] of this Agreement, Acclarent may optionally pay to Advanced the sum of [****] in order to continue to maintain exclusivity. All
payments relating to exclusivity shall be due on or before the anniversary date of this Agreement. Any failure to make any such payment within [****] of the anniversary date of this Agreement shall constitute grounds for Advanced to terminate the
exclusivity provided for in Section 3.1 above subject to the default notice and cure provisions of Section 14.2(b) below. However, any termination of exclusivity pursuant to this paragraph shall not relieve or alter the obligations of
Acclarent to Advanced relative to sole source supply (as defined in Section 3.4 below); SUBJECT, HOWEVER, to the conditions of Article 9 and the term of this Agreement as outlined in Article 14. 
 Provided that Acclarent has made its payments relative to exclusivity as outlined above, there shall be no minimum purchase requirement for Product,
other than what Acclarent has submitted via forecast to Advanced. In addition, again provided exclusivity payments are current, Advanced shall provide to Acclarent a [****] discount from the pricing set forth in Exhibit B for all Balloon
purchased by Acclarent. This discount shall apply up and until the total amount discounted reaches an amount equal to the exclusivity payment paid for that year. 
 3.4 Advanced as [****] Supplier for Acclarent. In further consideration of Advanced’s covenant of exclusive supply as identified above, Acclarent hereby agrees that, [****]; SUBJECT, HOWEVER, to the
following provision: 
 The pricing set forth in Exhibit B for the Product specified in Exhibit A shall remain in effect for [****].
After the [****] anniversary date of this Agreement, Acclarent shall [****]. 
 If Advanced has or subsequently acquires any Patent Rights
that would be infringed by Acclarent’s use of the technology transferred under this Agreement, Advanced will license Acclarent under such patent rights to use the technology transferred under this agreement without payment of any further
consideration by Acclarent unless agreed to by both parties. 
 If, at any time prior to the third anniversary of this Agreement, Acclarent
obtains a quote from a third party to fill an order for extruded tubing used in an Acclarent Product for resale and/or any non-compliant or semi-compliant balloons for resale having either a [****] that is not specified in Exhibit A, [****],
Acclarent shall be free to place the order with a third party. In the event, however, that Advanced is able to [****], then that order will be placed with Advanced [****]. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 If, at any time after the [****] of this Agreement, Acclarent obtains a quote from a third party to fill
an order for extruded tubing and/or any [****] that is not specified in Exhibit A, Advanced shall be given the opportunity to provide a competitive quote for such order and Acclarent will consider such quote from Advanced in good faith subject
to Acclarent’s business judgment. After the third anniversary of this Agreement Acclarent shall not be obligated to purchase any extruded tubing and/or any non-compliant or semi-compliant balloons having either a [****] that is not specified in
Exhibit A from Advanced even if Advanced quotes a price or terms that are more favorable than those quoted by third parties. 
 ARTICLE 4 - DELIVERY AND ACCEPTANCE OF PRODUCT 
 4.1 Delivery. Advanced shall cause all orders of Product to be
delivered [****] on or before the delivery date set forth in the applicable purchase order. In the event that Advanced is unable to deliver pursuant to said Purchase Order, Advanced shall notify Acclarent in writing of said expected shipping date.
Title and risk of loss of Product shall pass to Acclarent when [****]. 
 4.2 Shipping. The Product shall be shipped to the
destination set forth on the applicable purchase order according to a shipping method specified by Acclarent, or if none is so specified, according to Advanced’s standard shipping practices. Advanced shall insure each shipment of Product
against loss or damage occurring after [****]. 
 4.3 Certification, Inspection, Acceptance and Remedies. Advanced shall provide
certification assuring that the Product complies with the Specifications. Acclarent shall have the right to inspect each delivery of Product, within [****] days of receipt thereof, to determine whether the Product meets the Specifications. For
Specifications that can only be determined through destructive testing, Acclarent will have [****] days of receipt thereof to determine whether the Product meets Specifications. If Acclarent determines that any of the Product do not meet such
Specifications, it shall so notify Advanced in writing within the allowed period of inspection set forth above and shall return the defective Product to Advanced, at Advanced’s expense. If Advanced is not notified of such noncompliance within
the allowed period of inspection set forth above, [****]. Advanced agrees to promptly repair or replace, at Advanced’s option, at no cost to Acclarent, any rejected Product which does not conform to the Specifications, provided that such
nonconformity is not due to any failure by Acclarent or its agents or representatives to properly handle, maintain, or store Product and provided that Advanced agrees that such rejected Product does not conform to the Specifications. Provided that
Advanced has a) promptly (within [****] days of receipt of the allegedly defective Product) notified Acclarent in writing of Advanced’s agreement that the returned Product does not meet such Specifications and b) promptly repaired or
replaced such rejected Product at no cost to Acclarent, [****]. However, if Advanced has not a) promptly (within [****] days receipt of the allegedly defective Product) notified Acclarent in writing of its agreement that the returned Product
does not meet such Specifications and b) promptly repaired or replaced such rejected Product at no cost to Acclarent, then Acclarent shall be free to proceed in accordance with the dispute resolution procedure set forth in Section 16.10
below and shall be free to seek and obtain any and all remedies available at law or in equity under this Agreement. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 ARTICLE 5 - PRICE 
 5.1 Price. The purchase price of the Product shall be as set forth on Exhibit B attached hereto. It is expressly agreed that the pricing
shall be [****] for the first [****] of this Agreement. After the [****] of the effective date of this Agreement, Advanced may raise any prices for Product in proportion to any demonstrable increases in Advanced’s cost(s) for material and/or
labor and/or overhead provided that a) Advanced provides written notice of such price increase and documentation of the increases in its material and/or labor and/or overhead cost(s) to Acclarent at least sixty (60) days prior to the
effective date of such price increase and b) any such price increases will not exceed the cumulative change in the Consumer Price Index for the Boston, Massachusetts area that has occurred since the effective date of this Agreement. All prices
arc exclusive of, and Acclarent shall bear and be responsible for, all taxes, fees, duties or tariffs which may be levied upon Advanced by any government or governmental agency by reason of the sale or transport of Product hereunder, or measured by
the value thereof, other than taxes imposed on net income and taxes imposed by reason of any independent activity of Advanced. 
 5.2
Payment. The purchase price and other costs for Product supplied hereunder shall be invoiced by Advanced upon shipment. All undisputed amounts shall be due and payable [****] days after receipt of invoice. All disputed amounts must be
disputed in writing from Acclarent to Advanced within [****] days after receipt of invoice or such dispute shall be deemed waived. 
 ARTICLE 6 - REPRESENTATIONS 
 6.1 Representations by Advanced. Advanced represents and warrants to Acclarent
that: 
 (a) It is duly organized and validly existing under the laws of its state of incorporation and has frill corporate power and
authority to enter into this Agreement. 
 (b) It is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder. 
 (c) This Agreement is legally binding upon Advanced and enforceable in accordance with its terms. The execution, delivery and
performance of this Agreement by itself does not conflict with any material agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it. 
 (d) To the best of its knowledge, it has sufficient legal
and/or beneficial title and ownership under its intellectual property rights necessary for it to fulfill its obligations, and to the best of Advanced’s knowledge at the making of this Agreement, the use and purchase by Acclarent of the Product
and/or the use by Acclarent of the technology transferred under this Agreement will not infringe upon any patent rights of Advanced or any third party. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 6.2 Representations by Acclarent. Acclarent represents and warrants to Advanced that: 

(a) It is duly organized and validly existing under the laws of its state of incorporation and has full corporate power and authority to enter into
this Agreement. 
 (b) It is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder. 
 (c) This Agreement is legally binding upon Acclarent and enforceable in accordance with its terms. The execution, delivery and performance of this
Agreement by itself does not conflict with any material agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or
administrative or other agency having jurisdiction over it. 
 (d) To the best of its knowledge, it has sufficient legal and/or beneficial
title and ownership under its intellectual property rights necessary for it to fulfill its obligations pursuant to the terms of this Agreement. 
 ARTICLE 7 - WARRANTIES 
 7.1 Advanced warrants that its manufacturing facilities, manufacturing processes, raw
materials and all Product will: 
  

	 	(a)	conform in all material respects to the Specifications; 

  

	 	(b)	be manufactured in accordance with ISO 9001-2000 standards; 

  

	 	(c)	consist only of materials, Product and other items that are new; and 

  

	 	(d)	all other applicable laws and governmental regulations. 

 7.2 Advanced further warrants that it will not make any substantial changes in any Product or any materials or components used in the manufacture of any product without providing prior written notification to Acclarent of the specific
nature of such changes. 
 7.3 No Other Warranties. EXCEPT AS PROVIDED IN SECTIONS 7.1 and 7.2 ABOVE, OR AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, ADVANCED MAKES NO AND HAS MADE NO OTHER WARRANTIES, ORAL OR WRITTEN, REGARDING THE PRODUCT, AND HEREBY DISCLAIMS ANY IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
A PARTICULAR PURPOSE OR ANY IMPLIED WARRANTY ARISING OUT OF THE COURSE OF DEALING OF THE PARTIES. 

 ARTICLE 8 - INTELLECTUAL PROPERTY OWNERSHIP AND FUTURE 
 DEVELOPMENT PROJECTS 
 8.1 Acclarent
has in the past and may from time to time in the future seek input and/or proposals from Advanced for development and manufacturing or devices or components for use within the defined Field of Use. For future projects, upon receiving a written
request from Acclarent, Advanced will produce, a fee-for-service proposal and work plan to be negotiated by and between the parties on a project-by-project basis. If the parties reach agreement relative to the same, the parties will work to jointly
develop the project. Under these circumstances, the parties agree that the Resulting Intellectual Property shall be owned as follows: 
  

	 	a.	If Acclarent employees are the sole inventors of the Intellectual Property, Acclarent will own the Intellectual Property; 

  

	 	b.	If Advanced employees are the sole inventors of the Intellectual Property, Advanced will own the Intellectual Property. 

  

	 	c.	If both Acclarent and Advanced employees are the inventors of the Intellectual Property, the Intellectual Property shall be jointly owned. 

  

	 	d.	All resulting Intellectual Property, regardless of ownership, shall be governed by the following licensing arrangement: 

  

	 	i.	Acclarent will have a fully paid, royalty free, sublicensable exclusive license to the Resulting Intellectual Property [****]. 

  

	 	ii.	Advanced will have a fully paid, royalty free, sublicensable exclusive license to the Resulting Intellectual Property in all other fields. 

 8.2 Patent Prosecution. Acclarent shall have the sole right and discretion to make all decisions regarding patent protection, copyright
registration or other forms of legal protections with respect to Resulting Intellectual property owned by Acclarent under Section 8.1(a) above and Acclarent will solely control and bear the cost of applying for, prosecuting, obtaining and
maintaining any patent, copyright registration of other mode of legal protections therefore. Advanced shall have the sole right and discretion to make all decisions regarding patent protection, copyright registration or other forms of legal
protections with respect to Resulting Intellectual property owned by Advanced under Section 8.1(b) above and Advanced will solely control and bear the cost of applying for, prosecuting, obtaining and maintaining any patent, copyright
registration or other mode of legal protections therefore. Acclarent shall have the first option to evaluate all Resulting Intellectual Property that is jointly owned under Section 8.1(c) above and, in its sole discretion, elect whether or not
to pursue patent protection, copyright registration or other forms of legal protections, where the initial and subsequent filings, if any, are to occur, and determine whether the patent protection will continue to be sought or maintained. In
exchange, Acclarent shall bear all costs of searching, preparing, filing, prosecuting, and maintaining patent protection for such jointly owned Resulting Intellectual Property on which it elects to pursue patent protection, 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
copyright registration or other modes of legal protection. If Acclarent elects not to pursue patent protection, copyright registration or other modes of
legal protection in a country for any jointly owned Resulting Intellectual Property, Advanced may elect to pursue, at its own expense, such protection. In addition, if Acclarent files a patent application on any jointly owned Resulting Intellectual
Property with claims that are limited to the Field of Use, Advanced shall have the right to file and prosecute at its own expense additional patent applications, continuations, divisionals, etc., with claims that are not limited to the Field of Use.

 Each Party agrees to cooperate and assist the other Party in regard to the above provisions, provided, however, that any Party providing
assistance to the other Party with respect to any patent application, copyright registration or other mode of legal protection being sought shall be reasonably compensated by the other Party for time expended and out of pocket expenses incurred. In
cases where Advanced is the party providing assistance to Acclarent, Advanced shall be compensated for time expended based on the compensation schedule set forth in Section 3.2 above. In addition, under no circumstances shall Advanced be
required to disclose any of its confidential, proprietary or trade secret information in the course of any patent prosecution process. 
 8.3
Third Party Infringement. Advanced and Acclarent shall each give prompt notice to the other of any infringement of a Licensed Patent by any third party as may come to their knowledge. 
 It is agreed that Acclarent shall have the right to pursue legal action against infringement of any licensed patent by third parties. Acclarent shall
bear all costs of any such suit, and Advanced shall cooperate with Acclarent to provide such nonmonetary assistance as is reasonable in connection with such action. Any recovery of damages by Acclarent for any such suit shall be applied
(i) first to Acclarent in satisfaction of any costs of litigation incurred by Acclarent relating to the suit; (ii) second to Acclarent in the amount of any damages awarded for out-of-pocket costs and expenses incurred by Acclarent to the
extent such costs and expenses are not accounted for in (i) above; and (iii) the balance remaining from any recovery shall be retained as follows: (x) Advanced shall receive [****] percent of any damages received by Acclarent and
(y) Acclarent shall receive the balance of said funds. 
 Costs of litigation as referred to in the preceding paragraph shall include,
but not be limited to, such out-of-pocket expenses as court costs and court fees, reasonable travel expenses, reasonable charges for the professional services of outside counsel and experts, and shall exclude only the time that Acclarent’s
employees devote to such litigation. 
 8.4 Acclarent agrees that it shall, at its expense, defend Advanced (which for purposes of this
paragraph shall include Advanced’s officers, directors, employees, and/or any of its agents, licensors and licensees), and hold Advanced harmless against, and will indemnify Advanced against any loss or expense, including reasonable
attorney’s fees with respect to any assertion, dispute, claim, cause of action, settlement, ruling, verdict, judgment or other asserted demand alleged, asserted, levied, rendered, entered, made or brought against Advanced, relating to or
arising out of the manufacture, sale, offer for sale, and/or use of any Product manufactured to Acclarent’s Specifications, provided Advanced gives Acclarent prompt written notice of such assertion, dispute, 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
claim, cause of action, settlement, ruling, verdict, judgment or other asserted demand and gives Acclarent the right to maintain sole control of the defense
and negotiation for resolving such assertion, dispute, claim, cause of action, settlement, ruling, verdict, judgment or other asserted demand. 
 ARTICLE 9 – [****] PROVISION 
 At any time after the [****] of the effective date of this Agreement,
Acclarent or any successor or assignee of Acclarent shall have the right to [****], provided, however, that this [****] provision and the amount indicated herein specifically excludes the [****] as defined herein. In the event that this [****]
provision is exercised, all other provisions of this Agreement [****] shall remain in full force and effect for the remaining term of this Agreement. 
 ARTICLE 10 - [****] TECHNOLOGY 
 Concurrently with execution of this Agreement, [****]
and Advanced shall execute the [****] Agreement appended hereto as Exhibit C, [****]. 
 Advanced shall be compensated at the rates set
forth in Article 3.2 herein for any time expended relative to the [****] Agreement and the subject matter thereof 
 ARTICLE 11 -
LIMITATION ON LIABILITY 
 LIMITATION OF LIABILITY. EXCEPT WITH RESPECT TO ARTICLE 3, ARTICLE 12 AND 13, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL LOSS OR DAMAGES. IN ANY EVENT, EXCEPT [****]. 
 ARTICLE 12 - INDEMNIFICATION 
 12.1 Indemnification by Advanced. Advanced hereby indemnifies and holds harmless
and agrees to defend Acclarent, its Affiliates and their respective officers, directors, employees and agents from and against all liabilities, damages, losses, costs and expenses (including reasonable attorneys’ fees) arising out of claims,
suits or proceedings brought by a third party as a result of [****]. 
 12.2 Indemnification by Acclarent. Acclarent hereby
indemnifies and holds harmless and agrees to defend Advanced, its Affiliates and their respective officers, directors, employees and agents from and against all liabilities, damages, losses, costs and expenses (including reasonable attorneys’
fees) arising out of a) [****] and b) Acclarent agrees that it shall, at its expense, defend Advanced (which for purposes of this paragraph shall include Advanced’s officers, directors, employees, and/or any of its agents, licensors
and licensees), and hold Advanced harmless against, and will indemnify Advanced against any loss or expense, including reasonable attorney’s fees with respect to any assertion, dispute, claim, cause of action, settlement, ruling, verdict,
judgment or other asserted demand alleged, asserted, levied, rendered, entered, made or brought against Advanced 

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 
[****]; PROVIDED, however that nothing in this Agreement shall require Acclarent to defend, indemnify or hold harmless, Advanced or any of its officers,
directors, employees, agents, licensors and licensees with respect to any loss, expense, attorneys fees, or judgment resulting from or alleging [****]. 
 12.3 Procedure for Indemnification. Whenever an indemnified party becomes aware of a claim, suit or proceeding as to which it believes it is entitled to indemnification under this Article 12, it shall give
notice in writing to the indemnifying party, shall permit indemnifying party to assume exclusive control of the defense or settlement of the matter, and shall provide, at the expense of indemnifying party, all authority, information and assistance
which indemnifying party may reasonably request for purposes of such defense. An indemnified party may engage its own counsel, at its own expense, to monitor the defense of any such matter. In no event shall the indemnifying party be entitled to
settle any of the above-mentioned claims that could materially adversely affect the indemnified party without the indemnified party’s consent. 
 12.4 Survival. The obligations of indemnification, cooperation and subrogation under this Article 12 shall survive the termination of this Agreement for any reason. 
 ARTICLE 13 - CONFIDENTIALITY 
 13.1 Non-Use and Non-Disclosure. Each
party acknowledges and agrees that all the other party’s Confidential Information is confidential and proprietary to the disclosing party. Each party shall not use or disclose to any third party or Affiliate the other party’s Confidential
Information without the other party’s prior written consent for any purpose other than as permitted or required hereunder. Acclarent shall be free, however, to disclose some or all of the technology transferred under this Agreement to its
contractors, sublicensees or consultants provided that such contractors, sublicensees or consultants are bound by a written confidentiality agreement with Acclarent that contains non-use and non-disclosure provisions that are at least as restrictive
as those set forth in this Section. Each party shall take the same reasonable measures necessary to prevent any disclosure by its employees, agents, contractors, sub-licensees, or consultants of the other party’s Confidential Information as it
applies to the protection of its own Confidential Information. This provision shall include, and be extended to, the terms of the Mutual Confidentiality and Non-Disclosure Agreement previously executed by the parties. 
 It is expressly agreed and understood that under no circumstances shall Advanced be required to disclose any of its confidential, trade secret or
proprietary processes, unless required by a Court of Law to do so. 
 13.2 Exclusions. Information shall not be considered
Confidential Information hereunder if it: 
 (a) was already in the possession of the receiving party prior to its receipt
from the disclosing party, as shown by the receiving party’s books and records; 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 (b) is, or becomes, part of the public knowledge or literature through no fault, act or
omission of the receiving party, provided, Confidential Information relating to the Product shall not be deemed to have entered the public domain by reason of its having been filed with any regulatory agency; 
 (c) is, or becomes, available to the receiving party from a source other than the disclosing party, which source has rightfully obtained
the same information and has no obligation of confidentiality to the disclosing party with respect to it; or 
 (d) is
required to be revealed pursuant to law, provided, however, the receiving party which is under any such requirement of law shall give reasonable notice to the disclosing party of such requirement and shall cooperate with the disclosing party in
reasonable legal efforts to limit or mitigate any such revelation so as to preserve the proprietary nature of any Confidential Information contained therein. 
 13.3 Duration; Surviving Obligation. Each party’s obligations of non-use and non-disclosure of the other party’s Confidential Information shall apply during the term of this Agreement and shall also
survive for a period of [****] after its termination for any reason. The terms of the Mutual Confidentiality and Non-disclosure Agreement previously executed by the parties shall also survive the termination of this Agreement and shall be
enforceable in accordance with its terms. 
 ARTICLE 14 - TERM AND TERMINATION 
 14.1 Term of Agreement. Unless terminated as provided in Section 14.2 below, the term of this Agreement shall commence on the Effective Date
and shall continue for a period of [****] years thereafter. Thereafter, this Agreement shall be automatically renewed for consecutive [****] year terms unless either party provides the other party with written notice of non-renewal at least
thirty (30) days prior to the commencement of the next renewal term. 
 14.2 Termination. This Agreement may be terminated prior
to the expiration of any term or renewal term as follows: 
 (a) Either party may terminate this Agreement at any time by
giving notice in writing to the other party if the other party files a petition of any type as to its bankruptcy, is declared bankrupt, becomes insolvent makes an assignment for the benefit of creditors, goes into liquidation or receivership, or
otherwise loses legal control of its business; 
 (b) Either party may terminate this Agreement at any time by giving notice
in writing to the other party if the other party is in material breach of this Agreement and has failed to cure such breach [****] of the receipt of written notice of breach from the non-breaching party; 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 (c) The parties may mutually agree in writing to terminate this Agreement for their
mutual convenience at any time and for any reason, subject to such terms and conditions as they may adopt. 
 14.3 Rights and Obligations
on Termination. If this Agreement is terminated or expires, the parties shall have the following rights and obligations: 
 (a) Termination or expiration of this Agreement shall not release either party from the obligation to make payment of all amounts then or thereafter due and payable. In any event, Advanced shall have no obligation to refund all or any
portion of the sums paid under 3.2 above; 
 (b) The parties’ respective rights and obligation under Articles 6
(Representations), Article 7 (Warranties), Article 11 (Limitation on Liability), Article 12 (Indemnification), Article 13 (Confidentiality) and Article 17 (General Provisions) shall survive such termination of this
Agreement. 
 (c) Acclarent may, in its sole option, request in writing that Advanced destroy all or any of the molds
manufactured for and paid for by Acclarent, and upon receipt of such written request Advanced will immediately destroy and certify in writing to Acclarent the destruction of such molds. 
 14.4 NO COMPENSATION. THE PARTIES AGREE THAT, SUBJECT TO THE ABOVE PROVISIONS OF SECTION 14.3, AND WITHOUT PREJUDICE TO ANY OTHER REMEDIES AT
LAW OR IN EQUITY THAT EITHER PARTY MAY HAVE IN RESPECT OF ANY BREACH OF THIS AGREEMENT, NEITHER PARTY SHALL BE ENTITLED TO OR CLAIM THAT IT IS ENTITLED TO ANY COMPENSATION OR LIKE PAYMENT AS A RESULT OF OR ARISING OUT OF [****], WHETHER
CLAIMED AS LOSS OF GOOD WILL, FOREGONE PROFITS, LOST INVESTMENTS, OR OTHERWISE. IN ANY EVENT, ADVANCED SHALL HAVE NO OBLIGATION TO [****]. 
 ARTICLE 15 - FORCE MAJEURE 
 Each of the parties hereto shall be excused from performance of its
obligations hereunder to the extent such performance is prevented by a cause beyond the reasonable control of such party, including, without limitation, acts of God; laws or governmental regulations that become effective subsequent to the effective
date of this Agreement war; insurrection; embargo; civil commotion; destruction of product facilities or materials by fire, earthquake or storm; labor disturbance; severe economic dislocation rendering the prices hereunder uneconomic or otherwise
insufficient; judicial action; and failure of public utilities or common carriers. 
 The above-paragraph specifically excludes regulatory
compliance necessary for manufacture of Product by Advanced and regulatory approvals necessary for marketing and sale of Product by Acclarent, from the FDA or other governmental regulatory agencies. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 ARTICLE 16 - GENERAL PROVISIONS 
 16.1 Entire Agreement. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and thereof and
supersede all the parties’ previous correspondence, term sheets, understandings, agreements and representations, oral or written, between the parties. 
 16.2 Relationship. The parties are independent contractors and shall not be deemed to have formed any partnership, joint venture or other relationship. Neither party shall make, or represent to any other person
that it has the power or authority to make, any financial or other commitment on behalf of the other party. 
 16.3 Assignment.
Neither party shall assign or otherwise transfer its rights or obligations under this Agreement except with the prior written consent of the other party; provided that no such consent for a transfer to an entity shall be required and all rights and
obligations arising hereunder shall inure to the benefit of and shall be binding upon that entity if it (a) is an Affiliate of either party, (b) is the successor in interest of one party by reason of sale, merger or operation of law, or
(e) has acquired all or substantially all of the assets and business of a party. Each party shall provide written notice of any such transfer to such an entity. 
 16.4 Amendment. This Agreement may not be modified or amended, in whole or in part, except by a written agreement signed by both parties. 
 16.5 Severability. If one or more of the provisions of this Agreement is subsequently declared invalid or unenforceable, this Agreement shall be
treated as though that provision were not in this Agreement, and this shall not affect the validity or enforceability of the remaining provisions of this Agreement (unless those provisions that are invalidated or unenforceable are clearly material
and inseparable from the other provisions). The Agreement as modified shall be applied and construed to reflect substantially the good faith intent of the parties and to achieve the economic effects originally intended by the terms hereof.

 16.6 Notices; Language. Except as may be otherwise provided in this Agreement, any notice, demand or request given, made or
required to be made shall be in writing and shall be effective, unless otherwise provided herein, when received after delivery by (a) registered air mail, postage prepaid; (b) facsimile with electronic confirmation of receipt; or
(c) by express mail or a reputable courier at the addresses set forth on the last page of this Agreement or to any other address that a party specifies in writing. Notices shall be provided as follows: 
 If to Advanced: Tricia LaFlamme Albert, Esquire/Corporate Counsel; Advanced Polymers, Inc., 29 Northwestern Drive, Salem, New Hampshire, 03079.
(603) 327-0612 (phone); (603) 327-0613 (fax). 
 If to Acclarent: Mr. Bill Facteau, President and CEO, Acclarent, Inc.,
1525-B O’Brien Drive, Menlo Park, California, 94025 with copy to Robert D. Buyan, Esq., Stout, Uxa, Buyan & Mullins, L.L.P., 4 Venture, Suite 300, Irvine, CA 92618. 

 16.7 Waiver. Either party’s failure or delay in exercising any remedy for default shall not
be deemed a waiver of that or any subsequent default of that provision or of any other provision hereof. 
 16.8 Counterparts. This
Agreement shall be executed in two or more counterparts, each of which shall be deemed an original. 
 16.9 Governing Law. In the
event that Acclarent should initiate a dispute pertaining to this Agreement, such dispute shall be governed by, and interpreted and construed in accordance with, the laws of the State of New Hampshire, excluding its choice of law rules. 

16.10 Dispute Resolution. Except for a claim arising under Article 9, or as otherwise provided in this Agreement, in the event that at any
time hereafter there arises any disagreement, controversy or dispute between the parties hereto with respect to the enforcement, violation or interpretation of this Agreement, or of the operations hereunder or of the respective rights and
liabilities of the parties hereto, then, upon written demand of any party hereto, said demand setting forth each matter or matters upon which the parties do not agree or upon which there is a controversy or dispute, after 30 days’ written
notice, such controversy or dispute shall be settled, in the first instance, by a meeting between the President of Acclarent and the President of Advanced, which meeting shall occur in a place mutually agreed upon by the parties. In the event that
said meeting is not successful in resolving any disputes between the parties, then such controversy shall be settled within thirty (30) days of said meeting between the President of Advanced and the President of Acclarent by mediation before
one mediator in accordance with the Commercial Arbitration Rules or, if applicable, the Patent Arbitration Rules, of the American Arbitration Association (such mediation to take place in New York, NY). If the parties are unable to resolve the
disagreement, controversy or dispute at that mediation, or within seven (7) days following such a mediation, said disagreement, controversy or dispute shall be resolved by binding arbitration before three arbitrators in accordance with the
Commercial Arbitration Rules or, if applicable, the Patent Arbitration Rules, of the American Arbitration Association, and judgment upon any award rendered by the arbitrators may be entered in any court having jurisdiction thereof The arbitrator(s)
shall set limits on discovery to assure that the arbitration will be concluded and the award rendered within no more than eight (8) months from selection of the arbitrator(s). The arbitrator(s) is/are authorized and empowered to grant equitable
relief including but not limited to permanent injunctions and restraining orders prohibiting or limiting disclosure or use of Confidential Information. The arbitrator(s) shall apply the substantive law of New York, except that the interpretation and
enforcement of this arbitration provision shall be governed by the Federal Arbitration Act. ANY AWARD BY THE ARBITRATOR(S) SHALL BE SUBJECT TO THE LIMITATIONS OF LIABILITY SET FORTH IN SUBSECTION 10.13 OF THIS AGREEMENT. The award may be confirmed
and enforced in any court of competent jurisdiction. Any post-award proceedings will be governed by the Federal Arbitration Act. Said arbitration shall take place in or within 20 miles of New York, NY. Each party hereto agrees to consider himself or
itself bound and to be bound by any award made by the arbitrators pursuant to this Agreement. If the disagreement, controversy or dispute is completed through arbitration, the prevailing party shall be entitled to its reasonable costs and reasonable
attorneys fees incurred in the mediation and arbitration. 

 16.11 Exhibits: The Exhibits appended to this Agreement contain material terms of this Agreement
and shall be deemed to be fully incorporated into and forming portions of this Agreement. 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the date first above
written. 
  

									
	 ACCLARENT
  
 ACCLARENT, INC.
	 		 	 ADVANCED
  
 ADVANCED POLYMERS, INC.

					
	By:	 	 /s/ William Facteau
	 		 	By:	 	 /s/ Mark A. Saab

		 	President & CEO	 		 		 	 President

					
		 	 1525-B O’Brien Drive
 Menlo Park, CA
94025
	 		 		 	 29 Northwestern Drive
 21 Salem, New Hampshire
03079

 Exhibit A 
  

	1.	Attach Acclarent catheter specifications: 

 [****]

  

	2.	Attach Advanced [****] Balloon specifications for Item Numbers: 

 [****] 
 Note: Advanced needs to create product specifications for these items that can be sent to Acclarent and Included herein.
The current specification contains lots of confidential information, which needs to be removed. 
 [****] 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 Exhibit B 
 Pricing 
 The following table lists the production pricing for the current [****] sizes with up to [****] and a
[****] up to [****]. These prices would apply to any balloon [****] and balloon from [****]. 
  

					
	 [****] of Forecast Quantity
(per size per calendar
year)
	  	 Price Per Balloon 
[****]
	  	 Price Per Balloon
[****]

	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]

 For any quantity over [****], the price breakdown will be based on [****] per machine, per shift, for [****].

 For [****], in the event that [****] of annual forecast for any Balloon of any size exceeds [****] for any calendar year during the term of this
Agreement, Acclarent and Advanced will negotiate in good faith to agree upon an amendment to the above-set- forth table based on the savings associated with high-volume processes associated with the [****], providing specific pricing for those
quantities of [****] and above. If Acclarent and Advanced are unable to agree upon such amendment to the above-set-forth table after a 30 day period of negotiation, either party may submit the matter for dispute resolution in accordance with
Section 16.10 of this Agreement and the arbitrator shall decide the pricing to be applied to quantities of [****] and above. 
 Standard [****]
R&D Costs 
 For existing balloon [****]. 
  

			
	Balloon Engineering Charge per balloon iteration:	  	[****]

 This charge includes the cost of the balloon mold which will be owned and depreciated by Acclarent subject to the
provisions of 14.3(c). 
  

			
	Minimum run of [****] balloons at [****] each ([****]/per size):	  	[****]

 [****] 
 The
following table lists the production pricing for [****] balloon sizes assuming identical specifications to the current [****] except for wall thickness [****]. This includes balloons with up to [****] and a rated [****] up to [****]. These prices
would apply to any balloon [****] and balloon [****]. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

					
	 [****] of Forecast Quantity
(per size per calendar
year)
	  	 Price Per Balloon 
[****]
	  	 Price Per Balloon
[****]

	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]
			
	 [****]
	  	[****]	  	[****]

 [****] 
 For [****]
balloons, in the event that [****] of annual forecast for any Balloon of any size exceeds [****] units for any calendar year during the term of this Agreement, Acclarent and Advanced will negotiate in good faith to agree upon an amendment to the
above-set-forth table based on the savings associated with high-volume processes associated with the [****], providing specific pricing for those quantities of [****] and above. If Acclarent and Advanced are unable to agree upon such amendment to
the above-set-forth table after a [****] period of negotiation, either party may submit the matter for dispute resolution in accordance with Section 16.10 of this Agreement and the arbitrator shall decide the pricing to be applied to quantities
of [****] and above. 
 For any [****] development work outside of the scope listed above Advanced will charge: [****] plus standard costs for extrusions and
balloon molds/tooling if required. 
 For all the services listed above, it is understood that as long as the Agreement is in force that Advanced will not
offer or provide substantially the same services to any other party on pricing or terms more favorable than those set forth above without also offering such more favorable pricing and/or terms to Acclarent. 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 Exhibit C 
 [****] AGREEMENT 
 [****] 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 First Amendment to Manufacture and Supply
Agreement dated March 31st, 2006 
 First Amendment to Manufacture and Supply Agreement by and between Acclarent, Inc., and Advanced Polymers, Inc., said Agreement being dated September 8, 2005. 
 Whereas, pursuant to Article 16.4, the parties have agreed to modify certain provisions of the Manufacture and Supply Agreement; and 
 Whereas, pursuant Article 16,4, the parties have agreed to amend the Agreement by deleting Article 2.4, 2.5 and 2.7 in their entirety and replacing
them with the following: 
 2.4. Forecasts. [****], Acclarent shall provide to Advanced a [****] rolling forecast (“Rolling Forecast”)
for Acclarent’s expected needs of Product. Updated Rolling Forecasts shall be provided by Acclarent no later than [****] it is due; in the event that Acclarent fails to provide an updated written forecast by [****] it is due, the Rolling
Forecast previously provided to Advanced shall constitute the forecast. (See Exhibit C for a graphical summary of the Rolling Forecast and Purchase Order scheduling.) 
  

	2.4.1	[****] Orders - Acclarent will purchase [****] via Purchase Order(s). 

  

	2.4.2	Forecasted Requirements - Acclarent and Advanced shall use Rolling Forecasts for planning purposes only. Advanced shall manufacture and supply Balloon Products solely on
Acclarent Purchase Orders according to the provisions of section 2.5 “Purchase Orders”. 

  

	2.4.3	Acclarent shall purchase product throughout the year [****] shown in Exhibit B. [****], Acclarent and Advanced will review the actual quantity of Product purchased. For Product
of which there was [****], Acclarent will pay the [****] actual quantity of purchased Balloon Products shown in Exhibit B. For Product of which there was [****], the review of actual quantities ordered and pricing will occur in November of the
next year. 

  

	2.4.4	[****], Acclarent and Advanced shall hold an annual Status Review to review the status of orders and consider planning issues such as new product launches, equipment purchases, etc.
Acclarent and Advanced shall cooperate to identify potential issues and develop mutually acceptable plans for addressing them. 

 2.5.
Purchase Orders. Acclarent shall submit written Purchase Orders or Change Orders for the purchase of its requirements for the Product, which set forth the quantities ordered, the requested delivery dates, shipping instructions, and
shipping address(es). Acclarent shall initiate a new Purchase Order (i.e. new PO number) [****] in a manner so that Advanced [****] purchase orders for Balloon Products. New line items shall be added to the appropriate Purchase Order on a monthly
basis via Change Orders in order to maintain the [****] Orders as defined above. 
 Pricing for Product (as outlined in Exhibit B) shall be based on actual
Product purchased (as described above in section 2.4). 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 Acclarent shall be entitled to use its standard form of purchase order; provided, however, that such purchase orders
shall not alter any of the terms contained in this Agreement. In the event of any conflict between the terms of any Purchase Order or Change Order delivered by Acclarent hereunder and the terms of this Agreement, the terms of this Agreement shall
control. The Purchase Order(s) will be amended with Change Orders. Any Change Order will reflect the original Purchase Order number submitted by Acclarent to Advanced, as well as quantities ordered, requested delivery dates, shipping instructions
and shipping address(es). 
 This Section shall also be subject to the terms of Article 3 below relating to exclusivity. 
 2.7. Purchase Order Lead Times. Acclarent shall provide Purchase Orders or Change Orders to Advanced [****] in advance of the delivery date for Balloons
that are [****] in advance of the delivery date for Balloons that are between [****]. Acclarent shall provide Purchase Orders or Change Orders to Advanced [****] in advance for assembled Balloon Catheters. 
 In WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written. 
  

					
	 ACCLARENT
  
 ACCLARENT, INC.
	 		 	 ADVANCED
  
 ADVANCED POLYMERS, INC.

			
	 /s/ James R. Zuegel
	 		 	 /s/ Mark A. Saab

	 VP Operations
	 		 	 President

			
	 1525-B O’Brien Drive
 Menlo Park. CA
94025
	 		 	 29 Northwestern Drive
 Salem, NH
03079

			
	Tel. 650-687-6022	 		 	Tel. 603-327-0606

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 Exhibit C 
 [****] 
  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 Second Amendment to Manufacture and Supply Agreement 
 Second Amendment to Manufacture and Supply Agreement by and between Acclarent, Inc., and Advanced Polymers, Inc., said Agreement being dated
November 30, 2006. 
 Whereas, pursuant to Article 16.4, the parties have agreed to modify certain provisions of the Manufacture
and Supply Agreement; and 
 Whereas, pursuant to Article 16.4, the parties have agreed to amend the Agreement by modifying
Article 2.4, 2.5, and 2.7, as follows: 
 A. The first paragraph of Article 2.4, Forecasts, shall be amended to change the
first sentence so that first sentence shall now read as follows (with the change being noted in italics): 
 2.4 Forecasts.
[****] during the term of this Agreement, Acclarent shall provide to Advanced a [****] month rolling forecast (“Rolling Forecast”) for Acclarent’s expected needs of Product and components. The balance of Article 2.4 shall
remain in full force and effect. 
 B. The first paragraph of Article 2.5, Purchase Orders, shall be amended to change the first
sentence so that first sentence shall now read as follows (with the change being noted in italics): 
 2.5 Purchase Orders or Chance
Orders. Acclarent shall submit written Purchase Orders or Change Orders for the purchase of [****] the Product, including component requirements, which set forth the quantities ordered, the requested delivery dates, shipping
instructions and shipping address(es). The balance of Article 2.5 shall remain in full force and effect. 
 C. Article 2.7,
Purchase Order Lead Times, shall be deleted in its entirety and replaced with the following: 
 2.7 Purchase Order Lead
Times. Acclarent shall provide Purchase Orders or Change Orders to Advanced [****] in advance of the delivery date for Balloons [****] in advance of the delivery date for Balloons [****], as well as for any components required by Acclarent.
Acclarent shall provide Purchase Orders or Change Orders to Advanced [****] in advance for assembled Balloon Catheters. 
 IN WITNESS
WHEREOF, the parties have caused this Amendment to be executed as of the date first written above. 
  

					
	 ACCLARENT
  
 ACCLARENT, INC.
	 		 	 ADVANCED
  
 ADVANCED POLYMERS, INC.

			
	 /s/ James R. Zuegel
	 		 	 /s/ Mark A. Saab

	 VP Operations
	 		 	 President

	 1525-B O’Brien Drive
 Menlo Park, CA
94025
	 		 	 29 Northwestern Drive
 Salem, NH
03079

	Tel. 650-687-6022	 		 	Tel. 603-327-0606

  

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]